Vera Therapeutics (VERA) Other financing activities (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Other financing activities data on file, last reported at $3.9 million in Q1 2026.

• Quarterly Other financing activities rose 157.14% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 16.86% YoY) and the FY2025 annual result came in at $7.0 million, down 47.95% from the prior year.
• Other financing activities fell to $3.9 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $6.9 million in Q1 2024 to a low of $47000.0 in Q2 2022.
• A 5-year average of $1.6 million and a median of $797000.0 in 2025 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities plunged 99.91% — and 2024, when it jumped 2779.58%.
• Tracing VERA's Other financing activities over 5 years: stood at $827000.0 in 2022, then slumped by 89.48% to $87000.0 in 2023, then jumped by 2556.32% to $2.3 million in 2024, then soared by 81.18% to $4.2 million in 2025, then retreated by 5.85% to $3.9 million in 2026.
• The last three Other financing activities figures came in at $3.9 million (Q1 2026), $4.2 million (Q4 2025), and $797000.0 (Q3 2025), per Business Quant data.